The history of copyright's flagship drug presents a nuanced case for stakeholders in the medicinal sector. While initially a blockbuster success, generating billions, the intellectual property end and the subsequent entry of generic competitors have significantly impacted earnings. This raises questions about the future profitability of analogous m